A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
- Sponsor:
- ECOG-ACRIN Cancer Research Group
- Sponsor Study ID:
- EA3231
- CTO #:
- 104154
- NCT Number:
- NCT06475989
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Thyroid
- Study Objectives:
- To compare progression free survival (PFS) in patients with BRAF V600Em differentiated thyroid cancer who progressed on frontline multikinase inhibitor treated with dabrafenib/trametinib or cabozantinib.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Kaczmar, John, at kaczmar@musc.edu , or please call +1 843-792-6691.
- Study Coordinator, Langley, Madelyn, at langlema@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina